+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Severe generalized exanthema due to etanercept given for severe plaque psoriasis



Severe generalized exanthema due to etanercept given for severe plaque psoriasis



Annals of Allergy, Asthma and Immunology 100(6): 621-622




(PDF emailed within 0-6 h: $19.90)

Accession: 055739132

Download citation: RISBibTeXText

PMID: 18592833

DOI: 10.1016/S1081-1206(10)60067-1


Related references

A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study. British Journal of Dermatology 176(3): 624-633, 2016

Clinical and economic impact of etanercept in real-life: a prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER). European Journal of Dermatology 23(6): 774-781, 2015

Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. Journal of the European Academy of Dermatology and Venereology 29(6): 1148-1155, 2016

Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis. Journal of the American Academy of Dermatology 70(1): E17-E18, 2014

Etanercept (Enbrel) for the treatment of moderate to severe plaque type psoriasis. Revue Medicale de Liege 61(3): 201-205, 2006

Etanercept combined with cyclosporine in a 6-year-old child with severe plaque psoriasis. Journal der Deutschen Dermatologischen Gesellschaft 14(10): 1042-1043, 2016

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). Journal of the European Academy of Dermatology and Venereology 29(2): 361-366, 2015

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. Journal of Dermatological Treatment 22(3): 138-143, 2011

Etanercept therapy for severe plaque psoriasis in a patient who underwent a liver transplant. Cutis 80(3): 211-214, 2007

Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology 26(6): 768-777, 2012

Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. European Journal of Dermatology 20(3): 323-328, 2010

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). Journal of Dermatology 44(4): 355-362, 2016

Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study. Journal of Drugs in Dermatology 11(3): 413-414, 2012

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. British Journal of Dermatology 165(3): 652-660, 2012

Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series. Journal of Cutaneous Medicine and Surgery 19(6): 561-569, 2015